Abstract
Introduction
The American Academy of Ophthalmology (2016-AAO) recommended hydroxychloroquine (HCQ) dose not to exceed 5 mg/kg/day (real body weight). Recently, it was reported that prescribed 2016-AAO dose provided adequate HCQ levels for most lupus nephritis (LN) patients, with low flare risk. However, the minimum HCQ dose required to keep adequate levels is unknown.
Objectives
To evaluate if a further reduction in 2016-AAO dose (2–3 mg/kg/day) would sustain 12-month HCQ levels in LN patients with stable inactive disease.
Methods
Seventy-three stable LN patients under prescribed full HCQ 2016-AAO dose for ≥6 months and adequate baseline HCQ levels (≥613.5 ng/mL) were divided in two groups: reduced 2016-AAO dose (2–3 mg/kg/day), n = 32, and full 2016-AAO dose (5 mg/kg/day), n = 41. All patients were assessed at baseline, 3, 6, and 12 months. HCQ levels were measured by liquid chromatography-tandem mass spectrometry. Flare was defined as augment ≥ 3 in SLE Disease Activity Index-2000 and/or change in treatment. Rigorous clinical/laboratorial surveillance was performed.
Results
Prospective evaluation revealed for reduced 2016-AAO dose group a decrease of HCQ levels from baseline to 3 months (1,404.9 ± 492.0 vs. 731.6 ± 385.0 ng/mL, p < 0.01), and sustained levels at 6 months (p = 0.273) and 12 months (p = 0.091) compared to 3 months. For the full 2016-AAO dose group, a decrease occurred only from baseline to 12 months (1343.5 ± 521.5 vs. 991.6 ± 576.3 ng/mL, p < 0.001). Frequencies of patients with inadequate levels at 6 months was higher in reduced 2016-AAO group than full 2016-AAO dose (59% vs. 24%, p = 0.005), as well as at 12 months (66% vs. 32%, p = 0.002). Six-month and 12-month flare frequencies were comparable for both groups (p > 0.05).
Conclusions
Prescribed HCQ low-dose regimen (2–3 mg/kg/day) does not sustain, for most patients, 6- and 12-month adequate HCQ levels. Full 2016-AAO dose maintained HCQ levels way above this limit.
Trail registration
ClinicalTrials.gov: NCT03122431, registered on April 20, 2017
Key Points • Reduced American Academy of Ophthalmology (2016-AAO) hydroxychloroquine (HCQ) dose (2–3 mg/kg/day, real body weight) is unable to sustain HCQ blood levels within the safe cut-off defined for flare risk. • Full 2016-AAO dose (5 mg/kg/day) maintains a safe pattern of HCQ levels up to 12 months. |
Similar content being viewed by others
Data availability
All data relevant to the study are included in the article, and the raw data will be provided to interested researchers whenever requested. The protocol was registered at ClinicalTrials.gov under number #NCT03122431.
References
Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, Criniti JM, Vásquez G, Massardo L, Duarte M, Barile-Fabris LA, García MA, Amigo MC, Espada G, Catoggio LJ, Sato EI, Levy RA, Acevedo Vásquez EM, Chacón-Díaz R, Galarza-Maldonado CM, Iglesias Gamarra AJ, Molina JF, Neira O, Silva CA, Vargas Peña A, Gómez-Puerta JA, Scolnik M, Pons-Estel GJ, Ugolini-Lopes MR, Savio V, Drenkard C, Alvarellos AJ, Ugarte-Gil MF, Babini A, Cavalcanti A, Cardoso Linhares FA, Haye Salinas MJ, Fuentes-Silva YJ, Montandon de Oliveira E Silva AC, Eraso Garnica RM, Herrera Uribe S, Gómez-Martín D, Robaina Sevrini R, Quintana RM, Gordon S, Fragoso-Loyo H, Rosario V, Saurit V, Appenzeller S, Dos Reis Neto ET, Cieza J, González Naranjo LA, González Bello YC, Collado MV, Sarano J, Retamozo S, Sattler ME, Gamboa-Cárdenas RV, Cairoli E, Conti SM, Amezcua-Guerra LM, Silveira LH, Borba EF, Pera MA, Alba Moreyra PB, Arturi V, Berbotto GA, Gerling C, Gobbi CA, Gervasoni VL, Scherbarth HR, Brenol JCT, Cavalcanti F, Costallat LTL, da Silva NA, Monticielo OA, Seguro LPC, Xavier RM, Llanos C, Montúfar Guardado RA, Garcia de la Torre I, Pineda C, Portela Hernández M, Danza A, Guibert-Toledano M, Reyes GL, Acosta Colman MI, Aquino AM, Mora-Trujillo CS, Muñoz-Louis R, García Valladares I, Orozco MC, Burgos PI, Betancur GV, Alarcón GS, Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR) (2018) First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis 77:1549–1557
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT (2019) Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736–745
Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF, American Academy of Ophthalmology (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394
Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW (2020) Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheum 72:448–453
Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Francès C, Wechsler B, Huong DLT, Ghillani P, Musset L, Lechat P, Piette JC (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54:3284–3290
Cunha C, Alexander S, Ashby D et al (2017) Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant 33:1604–1610
Pedrosa TN, Pasoto SG, Aikawa NE, Yuki EFN, Borba EF, Filho JCRF, Carricondo PC, Zanetti CB, Conde PG, Duarte NJC, Fontoura N, Romano P, Carvalho VM, Silva CA, Bonfa E (2020) Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. Lupus 29:560–568
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725–1725
Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291
Jallouli M, Galicier L, Zahr N, Aumaître O, Francès C, le Guern V, Lioté F, Smail A, Limal N, Perard L, Desmurs-Clavel H, le Thi Huong D, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacré K, Fain O, Stirnemann J, Cacoub P, Leroux G, Cohen-Bittan J, Sellam J, Mariette X, Blanchet B, Hulot JS, Amoura Z, Piette JC, Costedoat-Chalumeau N, the Plaquenil Lupus Systemic Study Group (2015) Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheum 67:2176–2184
McElnay J, Sidahmed A, Darcy P et al (1985) Chloroquine-digoxin interaction. Int J Pharm 26:267–274
Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453
Browning DJ (2014) Pharmacology of chloroquine and hydroxychloroquine. In: Hydroxychloroquine and chloroquine retinopathy. New York: Springer New York, pp. 35–63. doi:https://doi.org/10.1007/978-1-4939-0597-3_2
Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D, Furst DE (2002) Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 46:1460–1469
Raghoebar M, Peeters PA, Van den Berg WB et al (1986) Mechanisms of cell association of chloroquine to leucocytes. J Pharmacol Exp Ther 238:302–306
Schrezenmeier E, Dörner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155–166
AbuRahma AF, Alhalbouni S, Abu-Halimah S et al (2014) Impact of chronic renal insufficiency on the early and late clinical outcomes of carotid artery stenting using serum creatinine vs glomerular filtration rate. J Am Coll Surg 218:797–805
Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Petri M, Nived O, Snaith M, Sturfelt G (2000) The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol 27:373–376
WHO | Obesity. WHO. https://www.who.int/data/gho/data/themes/theme-details/GHO/body-mass-index-(bmi). Accessed on September 20, 2020.
Ghaussy NO, Sibbitt WL, Qualls CR (2001) Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol 28:2449–2453
Sumner LA, Olmstead R, Azizoddin DR et al (2019) The contributions of socioeconomic status, perceived stress, and depression to disability in adults with systemic lupus erythematosus. Disabil Rehabil 42:1264–1269
Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, Petri M, Karlson EW (2004) Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 50:849–857
Kaslow RA, Masi AT (1978) Age, sex, and race effects on mortality from systemic lupus erythematosus in the United States. Arthritis Rheum 21:473–479
Costedoat-Chalumeau N, Houssiau F, Izmirly P, Guern VL, Navarra S, Jolly M, Ruiz-Irastorza G, Baron G, Hachulla E, Agmon-Levin N, Shoenfeld Y, Dall'Ara F, Buyon J, Deligny C, Cervera R, Lazaro E, Bezanahary H, Leroux G, Morel N, Viallard JF, Pineau C, Galicier L, Vollenhoven RV, Tincani A, Nguyen H, Gondran G, Zahr N, Pouchot J, Piette JC, Petri M, Isenberg D (2019) A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther 106:374–382
Acknowledgements
We are grateful to all the research subjects for their gentle collaboration. We thank Elaine P. Leon and Nicole Fontoura from Laboratório de Investigação Médica 17 (LIM17) and Paschoalina Romano and Valdemir M. Carvalho and Divisão de Laboratório Central (DLC)—Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, for their support.
Funding
This work was supported by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) [#2015/03756-4 to SGP, NEA, CAS and EB; #2017/03983-6 for the LC-MS/MS system; #2017/14352-7 to TNP; and #2019/17272-0 to LVKK] and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) [#304984/2020-5 to CAS; #306879/2018-2 to EFB; and #305242/2019-9 to EB].
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval and consent to participate
The present study was approved by the Local Ethical Committee (Ethics Committee for Research Projects Analysis of Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil) (#39705014.6.0000.0068), and a signed informed consent form was obtained from all research subjects.
Disclosure statement
The authors declared no potential conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zanetti, C.B., Pedrosa, T., Kupa, L.d.V.K. et al. Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial. Clin Rheumatol 40, 2745–2751 (2021). https://doi.org/10.1007/s10067-021-05600-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-021-05600-2